Literature DB >> 19783895

The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography whole body imaging in the evaluation of focal thyroid incidentaloma.

G Zhai1, M Zhang, H Xu, C Zhu, B Li.   

Abstract

BACKGROUND: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a non-invasive whole-body imaging technique used to evaluate various types of malignancies. Recent advances have rapidly developed it into a diagnostic imaging tool in oncology.
OBJECTIVES: In this study, the prevalence of thyroid incidentaloma and its cancer risk rate were investigated by 18F-FDG PET/CT. The threshold of maximal standardized uptake value (SUVmax) for differentiation of benign and malignant tumors was also defined.
METHODS: From June 2007 to December 2008, 3600 subjects underwent 18F-FDG PET/CT in our department. Among the population under study, 115 subjects developed focal increased 18F-FDG uptake as thyroid incidentalomas and their SUVmax were analyzed qualitatively and semi-quantitatively.
RESULTS: Data from the 18F-FDG PET/CT study suggested that overall prevalence of thyroid incidentaloma was 3.2% (115/3580). Among the 96 incidentalomas (20 confirmed by surgery; 76 confirmed by fine-needle aspiration) with additional cyto- and histopathological diagnoses, 50% were malignant thyroid lesions. Therefore, the cancer risk of thyroid incidentaloma was 50%. SUVmax values of the malignant samples were significantly higher than those of benign (p=0.00, p<0.05). A SUVmax above 8 tended to be malignant. A significant correlation between SUVmax and maximal diameter of the thyroid incidentaloma was also indicated.
CONCLUSIONS: Thyroid incidentaloma detected by 18FFDG PET/CT has higher risk rate for thyroid malignancy; SUVmax can be used for differentiating benign from malignant thyroid tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19783895     DOI: 10.1007/bf03346574

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  17 in total

Review 1.  Nonpalpable thyroid nodules--managing an epidemic.

Authors:  Douglas S Ross
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

Review 2.  18F-fluorodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer.

Authors:  M P Stokkel; K G Moons; F W ten Broek; P P van Rijk; G J Hordijk
Journal:  Cancer       Date:  1999-12-01       Impact factor: 6.860

3.  Incidental focal thyroid uptake on FDG positron emission tomographic scans may represent a second primary tumor.

Authors:  C D Ramos; R Chisin; H W Yeung; S M Larson; H A Macapinlac
Journal:  Clin Nucl Med       Date:  2001-03       Impact factor: 7.794

4.  Chronic thyroiditis: diffuse uptake of FDG at PET.

Authors:  S Yasuda; A Shohtsu; M Ide; S Takagi; W Takahashi; Y Suzuki; M Horiuchi
Journal:  Radiology       Date:  1998-06       Impact factor: 11.105

5.  18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results.

Authors:  Lioe-Fee de Geus-Oei; Gerlach F F M Pieters; Johannes J Bonenkamp; Aart H Mudde; Chantal P Bleeker-Rovers; Frans H M Corstens; Wim J G Oyen
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

Review 6.  Thyroid incidentalomas. Prevalence, diagnosis, significance, and management.

Authors:  B Burguera; H Gharib
Journal:  Endocrinol Metab Clin North Am       Date:  2000-03       Impact factor: 4.741

7.  Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography.

Authors:  M S Cohen; N Arslan; F Dehdashti; G M Doherty; T C Lairmore; L M Brunt; J F Moley
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

8.  Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology.

Authors:  Jen-Der Lin; Tzu-Chieh Chao; Bie-Yu Huang; Szu-Tah Chen; Hung-Yu Chang; Chuen Hsueh
Journal:  Thyroid       Date:  2005-07       Impact factor: 6.568

9.  Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging.

Authors:  Joon Young Choi; Kyung Soo Lee; O Jung Kwon; Young Mog Shim; Chung-Hwan Baek; Keunchil Park; Kyung-Han Lee; Byung-Tae Kim
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

10.  Fine-needle aspiration biopsy of the thyroid: atypical cytopathological features.

Authors:  Moshe Yehuda; Richard J Payne; Raewyn M Seaberg; Christina MacMillan; Jeremy L Freeman
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-05
View more
  13 in total

1.  Incidence and Significance of Incidental Focal Thyroid Uptake on (18)F-FDG PET Study in a Large Patient Cohort: Retrospective Single-Centre Experience in the United Kingdom.

Authors:  Kanhaiyalal Agrawal; James Weaver; Fahim Ul-Hassan; Jean-Pierre Jeannon; Ricard Simo; Paul Carroll; Johnathan G Hubbard; Ashish Chandra; Hosahalli Krishnamurthy Mohan
Journal:  Eur Thyroid J       Date:  2015-06-11

2.  Benign and Malignant Thyroid Incidentalomas Are Rare in Routine Clinical Practice: A Review of 97,908 Imaging Studies.

Authors:  Abhineet Uppal; Michael G White; Sapna Nagar; Briseis Aschebrook-Kilfoy; Paul J Chang; Peter Angelos; Edwin L Kaplan; Raymon H Grogan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-07-09       Impact factor: 4.254

3.  Thyroid incidentaloma detected by fluorodeoxyglucose positron emission tomography/computed tomography: practical management algorithm.

Authors:  Inga-Lena Nilsson; Fabian Arnberg; Jan Zedenius; Anders Sundin
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

4.  Unfolding the role of PET FDG scan in the management of thyroid incidentaloma in cancer patients.

Authors:  Haim Gavriel; Adrian Tang; Ephraim Eviatar; Sor Way Chan
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-06       Impact factor: 2.503

5.  Incidental Focal (18)F-FDG Uptake in the Prostate: Clinical Significance and Differential Diagnostic Criteria.

Authors:  Suk Kyong Cho; Joon Young Choi; Jang Yoo; Miju Cheon; Ji Young Lee; Seung Hyup Hyun; Eun Jeong Lee; Kyung-Han Lee; Byung-Tae Kim
Journal:  Nucl Med Mol Imaging       Date:  2011-07-06

6.  ¹⁸F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study.

Authors:  Arnoldo Piccardo; Matteo Puntoni; Francesco Bertagna; Giorgio Treglia; Luca Foppiani; Federico Arecco; Raffaele Giubbini; Mehrdad Naseri; Angelina Cistaro; Manlio Cabria; Francesca Bardesono; Luca Ceriani; Fabio Orlandi; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-30       Impact factor: 9.236

Review 7.  The role of 18F-fluorodeoxyglucose positron emission tomography in thyroid neoplasms.

Authors:  Brian Hung-Hin Lang; Tsz Ting Law
Journal:  Oncologist       Date:  2011-03-04

8.  Ultrasound-guided laser ablation of incidental papillary thyroid microcarcinoma: a potential therapeutic approach in patients at surgical risk.

Authors:  Enrico Papini; Rinaldo Guglielmi; Hossein Gharib; Gharib Hosseim; Irene Misischi; Filomena Graziano; Marco Chianelli; Anna Crescenzi; Antonio Bianchini; Dario Valle; Giancarlo Bizzarri
Journal:  Thyroid       Date:  2011-05-19       Impact factor: 6.568

9.  F18-FDG-PET/CT thyroid incidentalomas: a wide retrospective analysis in three Italian centres on the significance of focal uptake and SUV value.

Authors:  Francesco Bertagna; Giorgio Treglia; Arnoldo Piccardo; Elisabetta Giovannini; Giovanni Bosio; Giorgio Biasiotto; El Khayat Bahij; Roberto Maroldi; Raffaele Giubbini
Journal:  Endocrine       Date:  2012-11-21       Impact factor: 3.633

10.  Risk of malignancy in focal thyroid lesions identified by (18)F-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography: evidence from a large series of studies.

Authors:  Ning Qu; Ling Zhang; Zhong-wu Lu; Wen-jun Wei; Yan Zhang; Qing-hai Ji
Journal:  Tumour Biol       Date:  2014-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.